The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to AstraZeneca (LON: AZN) and its partner Amgen Inc (NASDAQ: AMGN) for tezepelumab as a treatment for patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers, the multinational pharmaceutical company announced on Friday.
Tezepelumab is a potential first-in-class new medicine that blocks thymic stromal lymphopoietin (TSLP), an upstream modulator of multiple inflammatory pathways.
The aim of the Breakthrough Therapy Designation is to expedite the development and regulatory review of medicines that are intended to treat a serious condition and have shown encouraging early clinical results.
Data from the Phase IIb PATHWAY trial was used to form the decision to grant the Breakthrough Therapy Designation. The trial demonstrated that tezepelumab resulted in a significant reduction in the annual asthma exacerbation rate compared with placebo in a broad population of severe asthma patients, irrespective of patient phenotype, including Type 2 (T2) biomarker status.
Current biologic therapies only target T2-driven inflammation.
AstraZeneca and Amgen are currently developing tezepelumab in the Phase III PATHFINDER clinical trial programme.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007